Trump’s Generic Drug Tariff Plan: Impact on Indian Pharma

Mumbai | July 22, 2026 

Donald Trump has outlined a staggered tariff regime for generic medicines imported into the United States, a move that could have long term implications for Indian pharmaceutical exporters. 

What Is Trump’s New Tariff Plan? 

Under the plan, generic drugs entering the US will continue to attract zero tariffs for two years starting August 1, 2026. Import duties will then rise to 100% from August 1, 2028, before doubling to 200% a year later, from August 2029. 

In a post on Truth Social, Trump said the policy was designed to “RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them.” 

Trump added that the objective of the policy was to protect the people of the United States, and that the policy on patented, branded or innovative drugs would remain unchanged, noting that pharmaceutical facilities were being built across America “at a level never seen before.” 

This generic drug tariff plan is separate from an earlier executive order Trump signed on April 2, which imposed a 100% tariff on imported branded pharmaceuticals, unless manufacturers agree to government backed pricing arrangements or shift production to the United States. That branded drug policy remains unaffected by the new generic tariff timeline. 

How Could This Impact India? 

India is the largest exporter of generic drugs to the US and is often referred to as the pharmacy of the world, supplying generic medicines to countries across the globe. 

According to a Global Trade Research Initiative report, India exported USD 9.7 billion worth of pharmaceuticals to the US in 2025, accounting for 38% of its total global pharma exports of USD 25.8 billion. Indian generic medicines are widely prescribed for hypertension, diabetes, cancer, infectious diseases and mental health. 

Companies including Sun Pharma, Dr Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma and Zydus Lifesciences have a significant presence in the US generics market, making the tariff roadmap an important long term consideration for their manufacturing and investment strategies. 

Nifty Pharma And Key Stocks React 

The Nifty Pharma index came under pressure following the announcement, falling 1.51% to 25,699.45. The broader market was also lower, with the Sensex down 675 points, or 0.9%, at 76,795, and the Nifty down 192 points, or 0.8%, at 23,995. India VIX rose 4.6%. 

Selling was broad based across the pharmaceutical pack. Lupin led the declines, down nearly 4%, followed by Piramal Pharma, Aurobindo Pharma and Gland Pharma, each down more than 3%. Ajanta Pharma, Glenmark Pharma, IPCA Laboratories, Zydus Lifesciences, Cipla, Alkem Laboratories, Dr Reddy’s Laboratories, Sun Pharma, Mankind Pharma and several other drugmakers also traded lower. 

Among Nifty 50 constituents, Cipla and Dr Reddy’s Laboratories were among the top losers, down 1.8% and 1.6% respectively. Sun Pharma was down 0.9%. 

Outlook 

The zero tariff period on generic drugs runs until August 2026, ahead of the phased increase to 100% in 2028 and 200% in 2029. The distinction between the announced policy and its eventual impact will depend on how Indian pharmaceutical companies adjust manufacturing and export strategies within this window. 

Stay updated on Indian equity and commodity markets. Read more market news on PL Capital → 

Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing.

This is a knowledge-sharing initiative by PL Capital. The information provided is only for educational purposes and should not be considered as financial advice & has no influence on the investment/trading decisions of any investors.

For detailed disclaimers/disclosure and Mandatory terms and conditions please visit our website https://www.plindia.com/regulatory-content/